Zelissen P M, Koppeschaar H P, Erkelens D W, Thijssen J H
Department of Endocrinology, University Hospital, Utrecht, The Netherlands.
Clin Endocrinol (Oxf). 1991 Oct;35(4):369-72. doi: 10.1111/j.1365-2265.1991.tb03550.x.
To test the hypothesis that the hyperendorphinaemia in obesity originates from outside the pituitary.
Intravenous administration of corticotrophin-releasing hormone (CRH) after overnight suppression with 2 mg of dexamethasone in normal-weight controls and in obese subjects before and after weight reduction.
Eleven obese females, age (mean +/- SEM) 30 +/- 2.1 years, body mass index (BMI) 41.2 +/- 1.9 kg/m2. Eight normal-weight females served as controls, age 26 +/- 2.1 years, BMI 21.4 +/- 0.5 kg/m2. Five obese subjects were also studied after weight loss of 18.4 +/- 1.0% of original weight.
Plasma beta-endorphin, ACTH and cortisol. Cortisol production rate in 24-hour urine. Basal (without dexamethasone suppression) plasma beta-endorphin levels.
Basal (without dexamethasone suppression) beta-endorphin levels were 7.7 +/- 0.8 pmol/l in the obese and 3.8 +/- 0.5 pmol/l in the control subjects (P less than 0.005). The degree of suppression of beta-endorphin after dexamethasone was similar in the obese (23.2 +/- 3.7%) and in the control subjects (28.2 +/- 0.12%). Administration of CRH following dexamethasone suppression resulted in a small but significant increase of plasma beta-endorphin in both obese (from 1.55 +/- 0.12 to 2.32 +/- 0.28 pmol/l) and control subjects (from 0.98 +/- 0.24 to 1.69 +/- 0.33 pmol/l). The groups did not differ regarding this response, nor regarding the release of ACTH and cortisol after CRH. Cortisol production rate was higher (P less than 0.001) in the obese (68.7 +/- 3.3 mumol/24 h) than in the controls (40.0 +/- 3.0 mumol/24 h). No correlation between cortisol production rate and basal beta-endorphin levels was found. Weight loss appeared to have no influence on cortisol production rate, basal beta-endorphin levels, or on the responses to dexamethasone or CRH.
Plasma beta-endorphin in obese subjects can be affected by manipulations of the hypothalamic-pituitary-adrenocortical axis; the hypothesis that the hyperendorphinaemia of obesity originates from outside the pituitary cannot be confirmed.
检验肥胖症患者高内啡肽血症起源于垂体之外的假说。
在正常体重对照组以及肥胖受试者体重减轻前后,于隔夜给予2毫克地塞米松抑制后静脉注射促肾上腺皮质激素释放激素(CRH)。
11名肥胖女性,年龄(均值±标准误)30±2.1岁,体重指数(BMI)41.2±1.9千克/平方米。8名正常体重女性作为对照,年龄26±2.1岁,BMI 21.4±0.5千克/平方米。5名肥胖受试者在体重减轻了原始体重的18.4±1.0%之后也接受了研究。
血浆β-内啡肽、促肾上腺皮质激素(ACTH)和皮质醇。24小时尿中皮质醇生成率。基础(未用地塞米松抑制)血浆β-内啡肽水平。
肥胖者基础(未用地塞米松抑制)β-内啡肽水平为7.7±0.8皮摩尔/升,对照者为3.8±0.5皮摩尔/升(P<0.005)。地塞米松后β-内啡肽的抑制程度在肥胖者(23.2±3.7%)和对照者(28.2±0.12%)中相似。地塞米松抑制后注射CRH导致肥胖者(从1.55±0.12升至2.32±0.28皮摩尔/升)和对照者(从0.98±0.24升至1.69±0.33皮摩尔/升)血浆β-内啡肽均有小幅但显著的升高。两组在这一反应方面以及CRH后ACTH和皮质醇的释放方面并无差异。肥胖者(68.7±3.3微摩尔/24小时)的皮质醇生成率高于对照者(40.0±3.0微摩尔/24小时)(P<0.001)。未发现皮质醇生成率与基础β-内啡肽水平之间存在相关性。体重减轻似乎对皮质醇生成率、基础β-内啡肽水平或对地塞米松或CRH的反应均无影响。
肥胖受试者的血浆β-内啡肽可受到下丘脑-垂体-肾上腺皮质轴调控的影响;肥胖症高内啡肽血症起源于垂体之外的假说未得到证实。